Q-omics provides the consensus-scored LINC00615 profile across patient tissues and cancer cell-line models. LINC00615 expression is associated with patient survival in 16 of 34 cancer types, with the highest sampling consensus in READ. Among the 18 cancer types available for tumor–normal comparison, LINC00615 is differentially expressed in 5, with the highest sampling consensus in KIRP. Additionally, LINC00615 RNA expression shows 6,325 significant pathway-activity associations, with the highest sampling consensus in STAD. Together, these results highlight READ, KIRP, and STAD as cancer lineages where LINC00615 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for LINC00615 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes LINC00615 survival associations across molecular data types. LINC00615 RNA expression shows survival associations in the most cancer types (16). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible LINC00615 RNA expression–survival associations across cancer types. High LINC00615 expression shows unfavorable associations in READ, LUAD, KIRP, UCEC and STAD, but favorable associations in LUSC. The READ Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify READ as the clearest survival context for LINC00615 RNA expression.
This table summarizes LINC00615 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 5. The strongest signals are observed in KIRP for RNA.
This table ranks reproducible tumor–normal expression differences for LINC00615. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. LINC00615 shows lower tumor expression in KICH and higher tumor expression in KIRP, LUSC, LUAD and KIRC. The KIRP box plot shows higher LINC00615 RNA expression in tumor versus normal tissue (log2 FC = +0.071, t-test p = .007).
This table shows molecular features associated with LINC00615 in patient tissues and cancer cell lines. In patient samples, LINC00615 shows the broadest associations at the RNA and protein expression levels, with STAD recurring as the lineage with the largest associated feature set.
